quote 27 Aug 2013 | 06:42 pm

ONXX, we bid you a fond adieu...

Stock Movers 27 Aug 2013 | 09:00 am

Other News To Note 27 Aug 2013 | 09:00 am

• Galderma Laboratories LP, of Fort Worth, Texas, said the FDA approved Mirvaso (brimonidine) topical gel, for the treatment of the facial erythema (redness) of rosacea in adults 18 years of age or ol...

Financings Roundup 27 Aug 2013 | 09:00 am

• Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it closed its private placement of unregistered convertible notes and unregistered warrants generating gross proceeds of $4.9 million. read m...

Nanoparticles Fight Metastases Specifically, or Not at All 27 Aug 2013 | 09:00 am

Nanotechnology is usually a great illustration of the old adage that as far as the media are concerned, there are two kinds of science stories: “Gee whiz” stories and “Oh crap” stories. When She Was ...

China Hastens to Establish Regulatory Biosimilars Framework 27 Aug 2013 | 09:00 am

SHANGHAI – Looking to lower costs and facilitate better health care outcomes, China is stepping up efforts to develop a regulatory framework and a market for biosimilars. read more

Rigel Dented on Asthma Miss; Fostamatinib Decision Looms 27 Aug 2013 | 09:00 am

Shares of Rigel Pharmaceuticals Inc. were dinged Monday morning after the company said it would discontinue development of Syk inhibitor R343 in allergic asthma following a Phase II miss, another setb...

Approval of Valchlor Triggers Actelion Merger for Ceptaris 27 Aug 2013 | 09:00 am

Malvern, Pa.-based Ceptaris Therapeutics Inc. received FDA marketing approval for its single asset, Valchlor (mechlorethamine) gel, for the topical treatment of stage IA and IB mycosis fungoides-type ...

Astrazeneca’s Gambit: $225M for Early Stage Amplimmune 27 Aug 2013 | 09:00 am

Astrazeneca plc’s buyout of Amplimmune Inc. for $225 up front could put the pipeline-strapped pharma giant high on the short list of leaders in combination immunotherapy, if the latter’s early stage c...

Amgen, Onyx Shake Hands and Close the Deal at $125 per Share 27 Aug 2013 | 09:00 am

In the end, Amgen Inc. and Onyx Pharmaceuticals Inc. got the deal done. The companies disclosed Sunday evening that the boards of directors of both companies unanimously approved Amgen’s acquisition o...